問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
詹明澄
下載
2025-10-01 - 2028-12-31
Condition/Disease
In NCFBE and chronic PsA transfer subjects, the effect of AZD0292 IV every 4 weeks (Q4W) compared with placebo on the incidence of moderate to severe acute lung exacerbations was evaluated.
Test Drug
AZD0292
Participate Sites7Sites
Recruiting7Sites
2019-10-01 - 2023-04-30
Participate Sites6Sites
Not yet recruiting1Sites
Recruiting4Sites
Terminated1Sites
2020-09-15 - 2025-12-31
Participate Sites12Sites
Recruiting6Sites
Terminated6Sites
2023-10-01 - 2026-12-31
Participate Sites10Sites
Recruiting10Sites
2022-01-01 - 2026-12-31
2023-06-01 - 2026-12-31
Participate Sites9Sites
Not yet recruiting3Sites
2021-03-01 - 2023-07-30
2021-03-01 - 2028-12-31
2023-02-01 - 2024-11-30
Participate Sites3Sites
Recruiting3Sites
2025-10-20 - 2030-07-11
Participate Sites4Sites
全部
